Related Experiment Video
Updated: Jun 7, 2025

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts
Published on: January 29, 2018
Bone turnover markers, and growth and bone parameters in infants participating in a vitamin D intervention study
Insights
Vitamin D3 supplementation did not affect bone metabolism markers amino-terminal propeptide of type 1 procollagen (P1NP) and carboxy-terminal crosslinked telopeptide of type 1 collagen (CTX-I) in infants. These markers associate with growth but not bone mineralization.
Area of Science:
- Pediatrics
- Nutritional Science
- Biochemistry
Background:
- Amino-terminal propeptide of type 1 procollagen (P1NP) and carboxy-terminal crosslinked telopeptide of type 1 collagen (CTX-I) are established biomarkers for bone turnover.
- Infant bone development is crucial, and vitamin D plays a significant role in calcium homeostasis and skeletal maturation.
- Understanding the impact of vitamin D supplementation on bone metabolism markers in infancy is essential for optimizing growth and bone health.
Purpose of the Study:
- To investigate the effect of two different daily vitamin D3 doses (10 μg vs. 30 μg) on P1NP and CTX-I levels in 12-month-old infants.
- To explore the relationship between these bone metabolism markers and anthropometric measurements, growth rates, and bone parameters in infants.
- To assess potential sex-specific differences in response to vitamin D supplementation regarding bone metabolism markers.
Main Methods:
- Secondary analysis of the randomized, double-blinded Vitamin D Intervention in Infants (VIDI) study involving 987 infants.
- Measurement of P1NP and CTX-I concentrations at 12 months of age in a subset of infants (n=812 for P1NP, n=786 for CTX-I).
- Assessment of anthropometrics and tibial bone parameters (bone mineral content, density, cross-sectional area, polar moment of inertia) using peripheral quantitative computed tomography (pQCT); calculation of growth rates from birth to 12 months.
Main Results:
- Vitamin D3 supplementation dose did not significantly influence mean CTX-I levels.
- A trend for lower P1NP levels was observed in girls compared to boys in the higher vitamin D group, suggesting a potential dose-dependent effect.
- P1NP positively correlated with growth rates in length and weight, while CTX-I showed inverse associations with length, weight, and weight growth rate; neither marker correlated with bone mineralization parameters.
Conclusions:
- Vitamin D3 supplementation at the tested doses did not alter P1NP or CTX-I levels in infants, indicating no significant impact on overall bone turnover markers.
- P1NP and CTX-I are associated with infant growth and body size, but not directly with bone mineralization at 12 months of age.
- The observed sex difference in P1NP response to higher vitamin D doses warrants further investigation into potential sex-specific effects on bone collagen matrix formation during infancy.
Abstract:
Amino-terminal propeptide of type 1 procollagen (P1NP) and carboxy-terminal crosslinked telopeptide of type 1 collagen (CTX-I) are markers of bone metabolism. We examined the effect of vitamin D3 supplementation on these markers and their relationship with growth and bone parameters in 12-month-old infants. In a randomized, double-blinded, vitamin D intervention in infants (VIDI) study, 987 infants received daily vitamin D3 supplementation of 10 μg (group-10) or 30 μg (group-30) from age 2 weeks to 24 months. We conducted a secondary analysis of the original VIDI trial. At 12 months of age, P1NP (n = 812) and CTX-I (n = 786) concentrations were analyzed, and anthropometrics and total bone mineral content, volumetric bone mineral density, cross-sectional area and polar moment of inertia of tibia were measured by peripheral quantitative computed tomography. The growth rate in weight and length was calculated from birth to 12 months. The vitamin D dose did not influence mean (SD) levels of CTX-I (group-10: 0.90 (0.31); group-30: 0.89 (0.31) (P > 0.53)). The mean difference of P1NP (CI 95%) comparing group-10 with group-30 was 35 (-103, 33) ng/mL (P = 0.31) in boys and -63 (-4, 130) ng/mL (P = 0.064) in girls. In group-10, girls had higher mean (SD) value of P1NP (1509 (362) ng/mL) than boys (1407 (297) ng/mL) (P = 0.003); no sex differences were observed in group-30 (girls: 1446 (359); boys: 1442 (359), P = 0.91) or CTX-I. P1NP associated positively with the growth rate in length (B (CI 95%) 0.0003 (0.0001, 0.001), P = 0.022) in the whole cohort but not in subgroups divided by the intervention group or sex, adjusted for birth size and parental heights and corrected for multiple testing. P1NP associated positively with the growth rate in weight (0.01 (0.0003, 0.01), P < 0.001). An inverse association was observed between CTX-I and length (cm) in the whole cohort (-0.90 (-1.40, -0.40), P = 0.005) and in group-30 (-1.05 (-1.72, -0.39), P = 0.011). Furthermore, CTX-I associated negatively with weight (SDS) in the whole cohort (-0.33 (-0.55, -0.12), P = 0.015) and the growth rate in weight (-0.43 (-0.66, -0.20), P = 0.005), persisting in group-30 and in boys but not in group-10 or in girls. Neither marker was associated with bone parameters. The observed sex difference in P1NP might suggest that a higher vitamin D dose resulted in a small decrease in bone collagen matrix formation in girls but not in boys. P1NP and CTX-I associate with growth and body size but not with bone mineralization in infancy.
Related Concept Videos
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Skeleton and Calcium Homeostasis
Bone Formation by Intramembranous Ossification
The process begins when mesenchymal cells in the embryonic skeleton gather together and differentiate into osteogenic cells, which then develop into ...
Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...

